(UroToday.com) The 2024 SUO annual meeting included a session on non muscle invasive bladder cancer, featuring a presentation by Dr. Ashish Kamat discussing BCG unresponsive cancer in 2024.
In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body ...
The American Red Cross Cell and Gene Therapy Solutions (CGTS) division, a leading single-source provider for allogeneic cell therapy source material, has selected Accellix, Inc., the developer of the ...